JP7628320B2 - 変性ｈｄｌの定量方法、及びそれに用いる分析用試薬 - Google Patents
変性ｈｄｌの定量方法、及びそれに用いる分析用試薬 Download PDFInfo
- Publication number
- JP7628320B2 JP7628320B2 JP2022512194A JP2022512194A JP7628320B2 JP 7628320 B2 JP7628320 B2 JP 7628320B2 JP 2022512194 A JP2022512194 A JP 2022512194A JP 2022512194 A JP2022512194 A JP 2022512194A JP 7628320 B2 JP7628320 B2 JP 7628320B2
- Authority
- JP
- Japan
- Prior art keywords
- hdl
- denatured
- denatured hdl
- binding protein
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 69
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 36
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 207
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 207
- 108010014172 Factor V Proteins 0.000 claims description 81
- 102100037814 Vigilin Human genes 0.000 claims description 80
- 108010092427 high density lipoprotein binding protein Proteins 0.000 claims description 80
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 claims description 57
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 210000002966 serum Anatomy 0.000 claims description 35
- 238000011002 quantification Methods 0.000 claims description 32
- 238000002965 ELISA Methods 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 238000003018 immunoassay Methods 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 claims description 5
- 108010054218 Factor VIII Proteins 0.000 claims description 5
- 102000001690 Factor VIII Human genes 0.000 claims description 5
- 101710191666 Lactadherin Proteins 0.000 claims description 5
- 102100039648 Lactadherin Human genes 0.000 claims description 5
- 229960000301 factor viii Drugs 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 230000035945 sensitivity Effects 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 238000005406 washing Methods 0.000 description 12
- 210000001124 body fluid Anatomy 0.000 description 10
- 239000010839 body fluid Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 108010064060 high density lipoprotein receptors Proteins 0.000 description 3
- 102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000000503 lectinlike effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101000722029 Homo sapiens Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000016610 Oxidized LDL Receptors Human genes 0.000 description 1
- 108010028191 Oxidized LDL Receptors Proteins 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 102000052513 human OLR1 Human genes 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/7456—Factor V
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020059965 | 2020-03-30 | ||
| JP2020059965 | 2020-03-30 | ||
| PCT/JP2021/013229 WO2021200797A1 (ja) | 2020-03-30 | 2021-03-29 | 変性ｈｄｌの定量方法、及びそれに用いる分析用試薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021200797A1 JPWO2021200797A1 (https=) | 2021-10-07 |
| JP7628320B2 true JP7628320B2 (ja) | 2025-02-10 |
Family
ID=77929007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512194A Active JP7628320B2 (ja) | 2020-03-30 | 2021-03-29 | 変性ｈｄｌの定量方法、及びそれに用いる分析用試薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230288437A1 (https=) |
| EP (1) | EP4130030A4 (https=) |
| JP (1) | JP7628320B2 (https=) |
| CN (1) | CN115698713A (https=) |
| WO (1) | WO2021200797A1 (https=) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003006989A1 (fr) | 2001-07-12 | 2003-01-23 | Kyowa Medex Co., Ltd. | Procede de quantification de lipoproteines denaturees, reactifs pour la quantification de lipoproteines denaturees, procede de detection de maladies du systeme circulatoire et reactifs pour la detection de maladies du systeme circulatoire |
| US20100055796A1 (en) | 2007-04-11 | 2010-03-04 | Markku Ahotupa | Estimation and biological consequences of oxidative metabolism |
| JP4671823B2 (ja) | 2004-09-27 | 2011-04-20 | シスメックス株式会社 | 血液凝固因子の不活化方法及び血液凝固因子不活化試料 |
| WO2015098901A1 (ja) | 2013-12-27 | 2015-07-02 | 独立行政法人国立循環器病研究センター | 抗血液凝固剤 |
| WO2018079674A1 (ja) | 2016-10-31 | 2018-05-03 | 国立大学法人大阪大学 | 脂質異常症治療が必要な被検者の選別方法及び選別用試薬 |
| WO2019159934A1 (ja) | 2018-02-14 | 2019-08-22 | 国立大学法人信州大学 | 融合タンパク質、及びそれを用いた高密度リポタンパク質の測定キット |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2200980C (en) | 1994-11-30 | 2009-09-22 | Tatsuya Sawamura | Mammalian receptors for modified low-density lipoprotein |
| JP3436444B2 (ja) * | 1995-07-21 | 2003-08-11 | ヤマサ醤油株式会社 | 酸化ｈｄｌの測定法及びキット |
| ATE512982T1 (de) * | 2001-08-17 | 2011-07-15 | Exothera L L C | Verfahren und zusammensetzung zum gezielten einbringen in exosome |
| JP2003279571A (ja) * | 2002-03-20 | 2003-10-02 | Kyowa Hakko Kogyo Co Ltd | 炎症性疾患検出方法、検出薬、およびその予防治療薬探索方法 |
| JP5706669B2 (ja) | 2010-11-10 | 2015-04-22 | 独立行政法人国立循環器病研究センター | 融合タンパク質、核酸、ベクター、細胞、ｌａｂの測定方法、並びに、ｌａｂ測定用キット |
| JP6231307B2 (ja) | 2013-06-27 | 2017-11-15 | 中野 恵正 | 機能不全ｈｄｌの測定方法、機能不全ｈｄｌ測定用キット、並びに、生活習慣病マーカーの測定方法 |
| JP6096360B1 (ja) | 2016-08-12 | 2017-03-15 | 旭サナック株式会社 | ワーク姿勢変更装置および多工程圧造機 |
| CN109580960A (zh) * | 2019-01-14 | 2019-04-05 | 周明 | 细胞外囊泡的分离方法、以及检测细胞外囊泡表面标志物的方法和试剂盒 |
-
2021
- 2021-03-29 US US17/907,746 patent/US20230288437A1/en active Pending
- 2021-03-29 EP EP21781075.3A patent/EP4130030A4/en active Pending
- 2021-03-29 CN CN202180037523.1A patent/CN115698713A/zh active Pending
- 2021-03-29 WO PCT/JP2021/013229 patent/WO2021200797A1/ja not_active Ceased
- 2021-03-29 JP JP2022512194A patent/JP7628320B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003006989A1 (fr) | 2001-07-12 | 2003-01-23 | Kyowa Medex Co., Ltd. | Procede de quantification de lipoproteines denaturees, reactifs pour la quantification de lipoproteines denaturees, procede de detection de maladies du systeme circulatoire et reactifs pour la detection de maladies du systeme circulatoire |
| JP4671823B2 (ja) | 2004-09-27 | 2011-04-20 | シスメックス株式会社 | 血液凝固因子の不活化方法及び血液凝固因子不活化試料 |
| US20100055796A1 (en) | 2007-04-11 | 2010-03-04 | Markku Ahotupa | Estimation and biological consequences of oxidative metabolism |
| WO2015098901A1 (ja) | 2013-12-27 | 2015-07-02 | 独立行政法人国立循環器病研究センター | 抗血液凝固剤 |
| WO2018079674A1 (ja) | 2016-10-31 | 2018-05-03 | 国立大学法人大阪大学 | 脂質異常症治療が必要な被検者の選別方法及び選別用試薬 |
| WO2019159934A1 (ja) | 2018-02-14 | 2019-08-22 | 国立大学法人信州大学 | 融合タンパク質、及びそれを用いた高密度リポタンパク質の測定キット |
Non-Patent Citations (3)
| Title |
|---|
| KAKINO, A. et al.，A Novel Cell-free, Non-Fluorescent Method to Measure LOX-1-Binding Activity Corresponding to The Functional Activity of HDL，Journal of Atherosclerosis and Thrombosis，2019年，Vol.26, No.11，pp.947-958 |
| KAKINO, A. et al.，A NOVEL METHOD TO QUANTIFY THE BIOLOGICAL ACTIVITY OF MODIFIED HDL，International Symposium on Atherosclerosis (ISA) 2018 Abstract Book，2018年06月05日，Vol.32, P1.008，p.35 |
| 垣野明美 ほか，変性HDL活性測定系の樹立とリスク評価への有用性の検討，日本生化学会大会プログラム・講演予稿集，2019年，第92回, 2P-386，pp.706-707 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4130030A4 (en) | 2024-03-27 |
| EP4130030A1 (en) | 2023-02-08 |
| CN115698713A (zh) | 2023-02-03 |
| WO2021200797A1 (ja) | 2021-10-07 |
| US20230288437A1 (en) | 2023-09-14 |
| JPWO2021200797A1 (https=) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240103018A1 (en) | Galectin-3 immunoassay | |
| EP2005168A2 (en) | Methods and compositions for the diagnosis of diseases of the aorta | |
| JP2012530900A (ja) | リポタンパク質特異的アポリポタンパク質を測定する方法 | |
| EP2095106A2 (en) | Methods and compositions for diagnosis and prognosis of renal artery stenosis | |
| JP3654912B2 (ja) | 虚血性疾患の検出または予知方法 | |
| JP6231307B2 (ja) | 機能不全ｈｄｌの測定方法、機能不全ｈｄｌ測定用キット、並びに、生活習慣病マーカーの測定方法 | |
| JP4523587B2 (ja) | Ａ型及びｂ型急性大動脈解離と急性心筋梗塞の鑑別方法及び鑑別用キット | |
| US7659125B2 (en) | Latex reagent for adiponectin analysis and method of adiponectin analysis | |
| JP7628320B2 (ja) | 変性ｈｄｌの定量方法、及びそれに用いる分析用試薬 | |
| Irish et al. | Lipoprotein (a) concentration in diabetes: relationship to proteinuria and diabetes control | |
| US20030059370A1 (en) | In vivo diagnostic apparatus and methods thereof | |
| Lin et al. | Positive interference from contrast media in cardiac troponin I immunoassays | |
| JP4580869B2 (ja) | 急性大動脈解離の判定方法及び判定用試薬 | |
| JP2011038858A (ja) | 血栓症の早期診断のための検査方法と検査試薬およびキット | |
| Hafner et al. | Comparison of diagnostic performance of cardiac troponin I on the IMMULITE system with other automated troponin I assays in minor myocardial damage | |
| JP7719507B2 (ja) | アディポネクチンの定量方法及びそれに用いる分析用試薬 | |
| WO2009099228A1 (ja) | 心不全の予知および検査方法と検査試薬およびキット | |
| JP6558729B2 (ja) | 糸球体障害の検査方法 | |
| HK40072995A (en) | Galectin-3 immunoassay | |
| JP2008516218A (ja) | 急性冠症候群の疑いを除外するｉｎｖｉｔｒｏ診断方法 | |
| WO2007119481A1 (ja) | 血中腸型脂肪酸結合蛋白測定による急性腸炎診断 | |
| JP2007093312A (ja) | Ｈ−ｆａｂｐ及びｄ−ダイマーによる急性大動脈解離の鑑別方法および鑑別用キット | |
| Bock | Test strategies for the detection of myocardial damage | |
| JP2006337322A (ja) | 血栓形成マーカーおよびその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240910 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7628320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |